Search results
Showing 151 to 165 of 202 results for sepsis
This guideline covers the clinical care of adults (18 years and over) who are dying during the last 2 to 3 days of life. It aims to improve end of life care for people in their last days of life by communicating respectfully and involving them, and the people important to them, in decisions and by maintaining their comfort and dignity. The guideline covers how to manage common symptoms without causing unacceptable side effects and maintain hydration in the last days of life.
CytoSorb for reducing risk of bleeding during cardiac surgery (MIB249)
NICE has developed a medtech innovation briefing (MIB) on CytoSorb for reducing risk of bleeding during cardiac surgery .
The appeal panel is drawn from a group of people approved by the Secretary of State for Health and Social Care to hear appeals.
Patient Status Engine for wireless monitoring of vital signs (MIB271)
NICE has developed a medtech innovation briefing (MIB) on the Patient Status Engine for wireless monitoring of vital signs .
This guideline covers when to offer and discuss caesarean birth, procedural aspects of the operation, and care after caesarean birth. It aims to improve the consistency and quality of care for women and pregnant people who are thinking about having a caesarean birth or have had a caesarean birth in the past and are now pregnant again.
NICE has developed a medtech innovation briefing (MIB) on the S-Cath System for suprapubic catheterisations
NICE has developed a medtech innovation briefing (MIB) on eXroid for internal haemorrhoids .
Chronic heart failure in adults: diagnosis and management (NG106)
This guideline covers diagnosing and managing chronic heart failure in people aged 18 and over. It aims to improve diagnosis and treatment to increase the length and quality of life for people with heart failure.
This guideline covers the care of women with a singleton pregnancy at increased risk of, or with symptoms and signs of, preterm labour (before 37 weeks), and women with a singleton pregnancy having a planned preterm birth. It aims to reduce the risks of preterm birth for the baby and describes treatments to prevent or delay early labour and birth.
Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)
Evidence-based recommendations on adalimumab (Humira) for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.
Servo-n with Neurally Adjusted Ventilatory Assist (NAVA) for babies and children (MIB163)
NICE has developed a medtech innovation briefing (MIB) on Serve-n with Neurally Adjusted Ventilatory Assist (NAVA) for babies and children .
This guideline covers diagnosing and managing epilepsy in children, young people and adults in primary and secondary care, and referral to tertiary services. It aims to improve diagnosis and treatment for different seizure types and epilepsy syndromes, and reduce the risks for people with epilepsy.
Show all sections
Sections for NG217
- Overview
- 1 Diagnosis and assessment of epilepsy
- 2 Information and support
- 3 Referral to tertiary specialist services
- 4 Principles of treatment, safety, monitoring and withdrawal
- 5 Treating epileptic seizures in children, young people and adults
- 6 Treating childhood-onset epilepsies
- 7 Treating status epilepticus, repeated or cluster seizures, and prolonged seizures
Neonatal infection guidance updated to allow home antibiotic treatment for some babies
We’ve recommended that newborn babies receiving antibiotics in hospital could potentially switch to oral antibiotics and be cared for at home if they are doing well and responding to treatment.
This quality standard covers the initial assessment and management of suspected acute respiratory infection in over 16s, including acute respiratory infection virtual wards.
View quality statements for QS210Show all sections
Sections for QS210
- Quality statements
- Quality statement 1: Documented initial assessment
- Quality statement 2: Prescribing antimicrobials
- Quality statement 3: Antibiotic duration
- Quality statement 4: Information about acute respiratory infection virtual wards
- Quality statement 5: Multidisciplinary team
- Quality statement 6: Support to self-manage on a virtual ward
- Quality statement 7: Virtual ward discharge summaries
Xpert GBS test for the intrapartum detection of group B streptococcus (MIB28)
NICE has developed a medtech innovation briefing (MIB) on Xpert GBS test for the intrapartum detection of group B streptococcus